Sohrab Fallahi
Rheumatology · Montgomery, ALNPI 1497739270
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,274 of the $24,815 with a category attached, or 61.6%. 32 manufacturers reported payments, led by Amgen at 47.4% of the total. Reporting peaked in 2019 at $9,698 and has fallen 77.9% since, to $2,141 in 2025.
Across 745 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$12K
- AbbVie$3K
- Novartis$1K
- Johnson & Johnson$1K
- Pfizer$1K
- Mallinckrodt Hospital Products Inc.$876
- plus $5K from 26 others
What the payments were for
- Speaking & faculty fees$9,20037%
- Travel & lodging$700%
- Food & beverage$15,27462%
- Education$2711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 122 | $11,774 |
| AbbVie | 161 | $3,299 |
| Novartis | 65 | $1,366 |
| Johnson & Johnson(2 entities) | 65 | $1,296 |
| Pfizer | 54 | $1,006 |
| Mallinckrodt Hospital Products Inc. | 29 | $876 |
| GSK | 43 | $865 |
| UCB, Inc. | 32 | $735 |
| AstraZeneca(2 entities) | 34 | $670 |
| Radius Health, Inc. | 25 | $487 |
| E.r. Squibb & Sons, L.L.C. | 24 | $449 |
| Aurinia Pharma U.S., Inc. | 16 | $374 |
| Genentech USA, Inc. | 18 | $355 |
| Boehringer Ingelheim | 12 | $295 |
| ANI Pharmaceuticals, Inc. | 6 | $173 |
| Fresenius Kabi USA, LLC | 7 | $132 |
| Octapharma USA, Inc. | 5 | $110 |
| Organon | 4 | $75 |
| Sanofi | 3 | $73 |
| Mallinckrodt Enterprises LLC | 3 | $66 |
| Bristol Myers Squibb | 3 | $62 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Hikma Pharmaceuticals USA | 3 | $48 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
| Bioventus LLC | 1 | $25 |
| Mylan Institutional Inc. | 1 | $24 |
| Sobi, Inc | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,815 in reported general payments places this provider in the 80th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 92 | $893,792 |
| ActharCorticotropin | 18 | $808,019 |
| EnbrelEtanercept | 87 | $670,259 |
| Humira(Cf) PenAdalimumab | 46 | $327,925 |
| RinvoqUpadacitinib | 46 | $326,600 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $119,847 |
| RemicadeInfliximab | 27 | $102,835 |
| Xeljanz XrTofacitinib Citrate | 13 | $101,620 |
| OrenciaAbatacept/Maltose | 12 | $63,608 |
| InflectraInfliximab-Dyyb | 20 | $51,670 |
| ProliaDenosumab | 28 | $47,733 |
| Hydroxychloroquine Sulfate | 370 | $26,290 |
| MethotrexateMethotrexate Sodium | 652 | $25,737 |
| Leflunomide | 100 | $12,454 |
| Risedronate Sodium | 50 | $11,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $876 | $808,01918 claims |
| AmgenEnbrel, Prolia | $11,774 | $717,992115 claims |
| AbbVieRinvoq | $3,299 | $326,60046 claims |
| Johnson & JohnsonRemicade | $1,296 | $102,83527 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $449 | $63,60812 claims |
| PfizerInflectra | $1,006 | $51,67020 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $7,80677 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Montgomery
- James JakesMontgomery$12K
- Jacquelin ChuaMontgomery$6K
- Pooja PoudelMontgomery$3K
- Anthony TurkiewiczMountain Brk$2.2M
- Jeffrey CurtisBirmingham$612K
- David McLainBirmingham$588K
- Ray McLaughinTuscaloosa$332K
- Elizabeth PerkinsHoover$264K
- Peter SawayMountain Brk$166K
- Kenneth SaagBirmingham$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.